Lv7
5010 积分 2022-09-07 加入
The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
5天前
已关闭
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
9天前
已完结
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer
9天前
已完结
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
10天前
已完结
The Distributional Characteristic and Growing Trend of Pancreatic Cancer in China: Erratum
1个月前
已关闭
Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target
2个月前
已完结
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
1年前
已完结
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
1年前
已完结
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
1年前
已完结
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
1年前
已完结
皖公网安备34019202002308
